XOMA (Details Narrative) - USD ($)	Jun. 03, 2024	Jun. 21, 2023	Sep. 30, 2024	Sep. 30, 2023
Milestone payment, amount		$ 6,000,000	$ 1,000,000
Payments for royalities		$ 6,000,000
XOMA [Member]
Royalty purchase agreement, description	Pursuant to the First Amendment, if the Company decides to commercialize aldoxorubicin itself, prior to the first commercial sale of aldoxorubicin, the Company and XOMA shall enter into a synthetic royalty purchase agreement, pursuant to which the Company shall agree to make quarterly royalty payments to XOMA equal to the amount of all aggregate net sales of aldoxorubicin during each calendar quarter multiplied by 1.5%. If the Company decides not to commercialize aldoxorubicin itself and instead licenses aldoxorubicin to a third party, upon entry of such a new license agreement, XOMA shall be entitled to receive (i) royalty payments with respect to net sales of aldoxorubicin payable to the Company multiplied by 7.5% and (ii) milestone payments of 7.5% of any milestone payable to the Company pursuant to the License Agreement
Assignment and assumption agreement description		Pursuant to the Assignment Agreement, the Company is entitled to receive (i) a one-time payment of $1 million upon acceptance of a re-submission of an NDA to the FDA for arimoclomol, and (ii) a one-time payment of $1 million upon the first invoiced sale in certain territories of a pharmaceutical product derived from arimoclomol as an active pharmaceutical ingredient, subject to the receipt of the applicable regulatory approval required to sell such a product in such countries. In January 2024, Zevra announced the FDA had accepted the NDA for arimoclomol and the Company received the one-time payment of $1 million in February 2024 recognized such net proceeds of $1.0 million as other income in the statement of operations for the period ended March 31, 2024
Royalty Purchase Agreement [Member]
Payments for royalities		$ 1,000,000
Aldoxorubicin and Arimoclomol [Member]
Legal fees		5,000,000
Arimoclomol [Member]
Milestone payment, amount			3,650,000
Commercial sale, amount		1,000,000
Aldoxorubicin [Member]
Milestone payment, amount			$ 316,000	$ 316,000
Commercial sale, amount		$ 4,000,000